전임상 이미징 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Preclinical Imaging Market Summary

The preclinical imaging market size was estimated at USD 1.0 billion in 2024 and is expected to reach USD 1.6 billion by 2033, growing at a CAGR of 5.6% from 2025 to 2033. This growth is driven by the rising prevalence of chronic diseases, increasing investments in drug development, and growing demand for non-invasive imaging techniques.

The adoption of advanced imaging modalities for early-stage research, coupled with the expansion of translational research initiatives, further accelerates market expansion. Government initiatives, such as grants and funding programs from agencies such as the National Institutes of Health (NIH) in the U.S. and similar organizations in Europe and Asia, are providing substantial financial support for preclinical research. For instance, in September 2022, the NIH and DHHS invited research applications for milestone-driven preclinical vaccine development targeting Enterotoxigenic Escherichia coli (ETEC), Salmonella Paratyphi A, and Shigella species. The funding supported innovative vaccine optimization, production scale-up, safety, and efficacy testing, with up to USD 750,000/year over five years, aiming to accelerate candidate vaccines for diverse populations. Eligible applicants included higher education institutions, nonprofits, governments, and businesses. NIAID planned to award USD 5.2 million for 4-6 projects to advance vaccines through preclinical stages toward FDA IND submission. Such a rise of capital enables researchers to acquire cutting-edge equipment, develop novel imaging agents, and conduct more comprehensive preclinical studies. The increased availability of funding directly translates into a higher demand for preclinical imaging services and technologies, thereby driving market expansion.

Preclinical imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT), and ultrasound, offer non-invasive methods to visualize and quantify biological processes at the cellular and molecular levels in animal models. For instance, an April 2025 Nature Communications study on type I conventional dendritic cells (cDC1s) immunotherapy used PET imaging to noninvasively monitor immune responses and tumor dynamics in preclinical cancer models. Researchers used PET scans to track the enhanced infiltration and activation of tissue-resident memory T cells induced by cDC1 vaccination, correlating imaging signals with effective tumor control and relapse prevention.

This imaging approach provided real-time insights into the spatial and temporal aspects of immune memory formation within tumors, validating the therapy's efficacy beyond conventional assays. This capability is crucial for researchers to study disease progression, assess the impact of novel therapies, and optimize treatment strategies before clinical trials in humans.

Similarly, the high prevalence of these diseases in developed countries with well established research infrastructures and investment in R&D significantly boosts the focus on preclinical imaging for treatment development, thereby contributing to the market growth. Additionally, chronic disease-specific animal models such as genetically engineered mice are being used extensively in combination with imaging systems, increasing the need for platforms that support dynamic imaging protocols.

Neurodegenerative diseases such as Alzheimer's and Parkinson's are also key drivers for the adoption of preclinical imaging, particularly in CNS-focused drug discovery. For instance, according to the Alzheimer's Association, around 7.2 million Americans aged 65 years and above in the America have Alzheimer's in 2025, with 74% among these being aged of age 75 years or above. Small-animal PET, SPECT, and MR imaging modalities are critical in tracking protein aggregation, neuroinflammation, and synaptic activity in murine models. The rising global burden of dementia and the lack of curative therapies have contributed to the surge in early-stage drug screening programs using advanced imaging techniques.

Preclinical imaging has experienced significant transformation and improvement through the use of AI (Artificial Intelligence). The vast amount of imaging data generated is processed and analyzed with AI techniques, enabling researchers to gain important insights and accelerate their work. For example, in May 2023, Koninklijke Philips N.V. introduced the Philips CT 3500, an innovative high-throughput CT system designed to meet the needs of large-scale screening programs and routine radiology. The Philips CT 3500 features advanced image reconstruction capabilities and workflow improvements. These features provide the reliability, speed, and high-quality imaging needed for clinicians to confidently diagnose patients and enhance operational efficiency, even in challenging medical environments.

On the other hand, the restrictions placed on animal testing due to regulations enforced by organizations that protect animal rights are the major factors impeding the growth of the market. Therefore, the adoption of alternative methods, such as in-vitro tests, micro-dosing, computer-based models, virtual testing of new drugs, and the development of computerized databases for testing purposes, is rapidly increasing. However, modalities with non-invasive imaging techniques such as MRI and CT scans are making their way into the market.

Global Preclinical Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global preclinical imaging market on the basis of type, application, end use and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Modality
  • Optical Imaging (BLI & F)
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Single Photon Emission Computed Tomography (SPECT)
  • Computed Tomography (CT)
  • Ultrasound Imaging (US)
  • Photoacoustic Imaging (PAI)
  • Hybrid Imaging Systems
  • Bi-Modal
  • SPECT-CT
  • PET-CT
  • SPECT-PET
  • PET-MRI
  • Optical-CT
  • Others
  • Tri-Modal
  • PET-SPECT-CT
  • PET-SPECT-MRI
  • PET-CT-Optical
  • Others
  • Others
• Reagent
• Service
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery & Development
• Toxicology & Pharmacokinetics Studies
• Basic & Translational Research
• Disease Mechanism & Pathophysiology Studies
  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Immunology & Inflammation
  • Others
• Biomarker & Imaging Agent Validation
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharma and Biotech Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Preclinical Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Preclinical Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Preclinical Imaging Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Preclinical Imaging Type Market Movement Analysis
• 4.3. Global Preclinical Imaging Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Modality
  • 4.4.1. Modality market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Optical Imaging (BLI & F)
    • 4.4.2.1. Optical Imaging (BLI & F) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Magnetic Resonance Imaging (MRI)
    • 4.4.3.1. Magnetic Resonance Imaging (MRI) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Positron Emission Tomography (PET)
    • 4.4.4.1. Positron Emission Tomography (PET) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.5. Single Photon Emission Computed Tomography (SPECT)
    • 4.4.5.1. Single Photon Emission Computed Tomography (SPECT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.6. Computed Tomography (CT)
    • 4.4.6.1. Computed Tomography (CT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.7. Ultrasound Imaging (US)
    • 4.4.7.1. Ultrasound Imaging (US) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.8. Photoacoustic Imaging (PAI)
    • 4.4.8.1. Photoacoustic Imaging (PAI) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.9. Hybrid Imaging Systems
    • 4.4.9.1. Hybrid Imaging Systems market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9.2. Bi-Modal
      • 4.4.9.2.1. Bi-Modal market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.2. SPECT-CT
        • 4.4.9.2.2.1. SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.3. PET-CT
        • 4.4.9.2.3.1. PET-CT market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.4. SPECT-PET
        • 4.4.9.2.4.1. SPECT-PET market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.5. PET-MRI
        • 4.4.9.2.5.1. PET-MRI market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.6. Optical-CT
        • 4.4.9.2.6.1. Optical-CT market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2.7. Others
        • 4.4.9.2.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9.3. Tri-Modal
      • 4.4.9.3.1. Tri-Modal market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3.2. PET-SPECT-CT
        • 4.4.9.3.2.1. PET-SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3.3. PET-SPECT-MRI
        • 4.4.9.3.3.1. PET-SPECT-MRI market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3.4. PET-CT-Optical
        • 4.4.9.3.4.1. PET-CT-Optical market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3.5. Others
        • 4.4.9.3.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.10. Others
    • 4.4.10.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Reagent
  • 4.5.1. Reagent market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Service
  • 4.6.1. Service market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Preclinical Imaging Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Preclinical Imaging Application Market Movement Analysis
• 5.3. Global Preclinical Imaging Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Drug Discovery & Development
  • 5.4.1. Drug Discovery & Development market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Toxicology & Pharmacokinetics Studies
  • 5.5.1. Toxicology & Pharmacokinetics Studies market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Basic & Translational Research
  • 5.6.1. Basic & Translational Research market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Disease Mechanism & Pathophysiology Studies
  • 5.7.1. Disease Mechanism & Pathophysiology Studies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.2. Oncology
    • 5.7.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.3. Cardiology
    • 5.7.3.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.4. Neurology
    • 5.7.4.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.5. Infectious Diseases
    • 5.7.5.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.6. Immunology & Inflammation
    • 5.7.6.1. Immunology & Inflammation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7.7. Others
    • 5.7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Biomarker & Imaging Agent Validation
  • 5.8.1. Biomarker & Imaging Agent Validation market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Preclinical Imaging Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Preclinical Imaging End Use Market Movement Analysis
• 6.3. Global Preclinical Imaging Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharma and Biotech Companies
  • 6.4.1. Pharma and biotech companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Contract Research Organizations (CROs)
  • 6.5.1. Contract Research Organizations (CROs) market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Academic and Research Institutes
  • 6.6.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Preclinical Imaging Market: Regional Estimates & Trend Analysis By Type, Application, End Use

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement structure
    • 7.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement structure
    • 7.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement structure
    • 7.5.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement structure
    • 7.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement structure
    • 7.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement structure
    • 7.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement structure
    • 7.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement structure
    • 7.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement structure
    • 7.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement structure
    • 7.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement structure
    • 7.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement structure
    • 7.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement structure
    • 7.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement structure
    • 7.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement structure
    • 7.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement structure
    • 7.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement structure
    • 7.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement structure
    • 7.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement structure
    • 7.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement structure
    • 7.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement structure
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement structure
    • 7.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement structure
    • 7.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share analysis, 2025
• 8.4. Company Position Analysis
• 8.5. Company Categorization (Emerging Players, Innovators and Leaders)
• 8.6. Company Profiles
  • 8.6.1. Cubresa Inc.
    • 8.6.1.1. Company overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. Bruker Corporation
    • 8.6.2.1. Company overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. Revvity (PerkinElmer, Inc)
    • 8.6.3.1. Company overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. FUJIFILM VisualSonics
    • 8.6.4.1. Company overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. Mediso Ltd.
    • 8.6.5.1. Company overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. Rigaku (MILabs B.V.)
    • 8.6.6.1. Company overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. MR Solutions
    • 8.6.7.1. Company overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. Aspect Imaging
    • 8.6.8.1. Company overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. TriFoil Imaging
    • 8.6.9.1. Company overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Strategic initiatives
  • 8.6.10. Siemens Healthineers
    • 8.6.10.1. Company overview
    • 8.6.10.2. Financial performance
    • 8.6.10.3. Product benchmarking
    • 8.6.10.4. Strategic initiatives